Beta-1 Adrenergic Inhibition to Reduce Cardiac Injury and Inflammation After Subarachnoid Hemorrhage (BADCATS)
Madeleine Puissant
20 participants
Sep 23, 2024
INTERVENTIONAL
Conditions
Summary
To determine the effect of early metoprolol administration after non-traumatic subarachnoid hemorrhage (SAH).
Eligibility
Inclusion Criteria2
- >18 years of age
- Neuro-imaging confirmed non-traumatic subarachnoid hemorrhage
Exclusion Criteria10
- Traumatic cause of subarachnoid hemorrhage (e.g. fall, motor vehicle accident, other blunt trauma) as this is a different mechanism of hemorrhage.
- Other forms of traumatic or non-traumatic intracranial bleed including intracerebral hemorrhage (ICH), subdural hemorrhage, epidural hemorrhage
- Pregnancy (as the study medication, metoprolol, has FDA Pregnancy Category C rating)
- Unstable vital signs not amenable to beta-1 adrenergic receptor inhibitor (B1ARi) administration including:
- Systolic blood pressure < 80 mmHg not stabilized on vasopressor medications
- Heart rate < 50 bpm associated with hypotension
- Patients requiring vasopressor agents due to hypotension (SBP <80 mmHg)
- Other vital sign exclusion at the discretion of the treatment team
- Previous history of severe heart failure (Stage C or D Heart Failure and/or NYHA Class III or IV)
- Patient or legally authorized representative unwilling to provide informed consent
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Metoprolol Dosing: Metoprolol Injection (instructions: 5mg, once) Metoprolol Tab (25mg PO, q12 hours, timed to start 1hr after Metoprolol Injection, 6 doses) If unable to take PO medication, Metoprolol Injection (instructions, 5mg q6hrs for 12 doses) Continue for 72-hours of administration unless reaching stopping criteria
Placebo Dosing: Placebo Injection (instructions: 5mL NS, once) Placebo Tab (1 tab PO, q12 hours, timed to start 1hr after placebo injection, 6 doses) If unable to take PO medication, Placebo Injection (instructions, 5mL q6hrs for 12 doses) Continue for 72-hours of administration unless reaching stopping criteria
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06569212